

BIOphysical characterization of Helium and Oxygen ion beams for hadronTherapy



BIO 




Proposta di nuovo esperimento

INFN-CSNV


2023-25




Unità partecipanti



- **PV:** F. Ballarini, M. Carante, A. Facoetti, M. Pullia, A. Mairani (*da associare*)
- **NA:** L Manti *et al.* (RN)
- **Roma3:** A. Antoccia, F. Berardinelli, V. Dini
- Partners:
 - CNAO (Centro Nazionale di Adroterapia Oncologica)
 - HIT (Heidelberg Ion-beam Therapy centre)
 - Queen's University, Belfast, UK



Anagrafica PV



Francesca Ballarini (PA) 0.5


Mario Pietro Carante (RTDa) 0.2

Angelica Facoetti (CNAO) 0.5


Marco Pullia (CNAO) 0.2

Andrea Mairani (HIT, *da associare*) 0.2



FTE Pavia 2023: **1.6**




Motivation for He ions




- with respect to protons, ^4He has less lateral scattering and range straggling, and higher LET →
 - *higher dose conformity to tumour with higher RBE*
 - *reduced dose to surrounding healthy tissues*
 - *indications for paediatric and/or close-to-OAR radioresistant tumours*
- at HIT, a patient has already been treated with ^4He
- CNAO will have a new source accelerating ^4He by 2023




Motivation for O ions




- ^{16}O is more effective than ^{12}C ions \Rightarrow
 - *potential benefit against radioresistant tumours*
 - *greater insensitivity to cell-cycle variations*
 - *enhanced anti-angiogenic and anti-metastatic properties*
- both HIT and CNAO are also considering to use ^{16}O beams





Relative dose (left) and dose-averaged LET (right) distributions for various ions.
He offers the best peak-to-plateau ratio, O the best trade-off between high LET and fragment tail
Kantemiris et al., Medical Physics, 2011




Motivation of the project



- for protons, a constant RBE (= 1.1) is assumed in clinics, but for heavier ions ($Z > 1$) the RBE needs to be known precisely in every position of the SOBP (*mm resolution*)
- the RBE can be evaluated, basing both on *in vitro* (and *in vivo*) experimental data and on biophysical models
- while for C-ions many data and models are already available, for He- and O-ions more data and modelling studies are necessary




Main objectives



- need of *in vitro* and *in silico* pre-clinical data for ^4He and ^{16}O
⇒ main project aim:


Biophysical characterization of these new beams, by means of:

- radiobiology experiments, to evaluate the response of both tumoral and healthy (=non-tumoral) cells
 - modeling/simulations of the same endpoints, for interpreting the experimental results and making predictions where there are no data
 - microdosimetric measurements
- This will prove essential also for facility intercomparison between HIT and CNAO




Pavia activity

1. Computational radiobiology




- the simulation activities will be based on the **BIANCA biophysical model**, developed in Pavia
- BIANCA can simulate cell death and chromosome aberrations by different radiation qualities (=different ions and energies) and for different cell lines
- BIANCA can be interfaced to a radiation transport code or a TPS to predict the biological effects along therapeutic ion beams
- BIANCA has been already validated for C-ions (and protons)
- **in BIOHOT, BIANCA will be extended to He- and O-ions**, for the same cell lines used in the experiments




Pavia activity

1. Computational radiobiology- *continued*




In particular, the simulation outcomes will be compared with the following data obtained by the experimental partners:

- **cell survival** curves for a (pancreas) **tumour** cell line \Rightarrow evaluation of the RBE for tumour control
- **chromosome aberration** dose-response curves for two **normal** (=non tumoral) cell lines \Rightarrow evaluation of healthy tissue damage
- **DNA damage 'foci'**, which will be compared with the BIANCA parameter representing DNA 'critical lesions' \Rightarrow insights into the mechanisms of radiation-induced damage




Pavia activity

2. Radiobiology experiments




The experimental activities will be carried out based on the expertise of the CNAO radiobiology group on **biological scaffolds**:

- biological scaffolds are biological **structures derived from real tissues/organs** deprived of their cellular component, but preserving the structural and functional molecular units of the remaining extracellular matrix (ECM)
- **they mimic the *in vivo* environment**, promoting cell viability, proliferation, diffusion of oxygen and nutrients, etc.
- they have **already been used by the CNAO research group**, which for the first time ever used this system for radiobiological studies with photons and charged particles



Pavia activity


2. Radiobiology experiments - *continued*




Hepatic scaffolds
will be used:



- the scaffolds will be populated through the seeding of normal and/or tumour cells
- they will be then irradiated by He- and O-ions, and photons for comparison



Spese PV-2023



MISSIONI: 2 k€ (turni di misura a HIT-Heidelberg)

CONSUMO: 15 k€ per esperimenti radiobiologia (*reagenti per preparazione scaffolds, plastica e reagenti per coltura cellule, kit istochimica, kit immunoistochimica*)

INVENTARIABILE: 1.5 k€ per PC portatile da utilizzare per acquisizione dati durante i turni di misura presso CNAO e/o HIT

- **BUDGET INTERO PROGETTO:** ~30 k€ per Unit per year ⇒ ~90 k€ for 2023

